Sunday, April 5, 2026

Policy

Policy•Fierce Biotech•Apr 2, 2026

UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments

background ▾

• •UK secures unprecedented 0% tariffs on pharmaceutical exports to the US in exchange for a 25% effective price increase via NICE threshold adjustment, positioning it as the first country to achieve such tariff-free status
• •Major pharma leaders who previously criticized UK investment conditions (Lilly, BMS, AbbVie, GSK) have signaled willingness to reconsider UK operations, though responses remain cautiously measured pending implementation details
• •Watch for: speed of NICE threshold implementation, actual investment decisions from paused programs (Lilly Gateway Labs, Sanofi R&D, Merck London site), and whether the 25% price increase satisfies pharma expectations without triggering NHS budget pressure or political backlash

Bristol Myers SquibbAbbVieGlaxoSmithKline

→ Read original article

Market Access

Market Access•Fierce Biotech•Apr 3, 2026

Biopharma R&D pipeline shrinks for 1st time in 30 years: report

background ▾

• •First documented decline in global drug development pipeline in 30 years signals potential structural shift in biopharma R&D productivity and investment allocation
• •Top-tier companies are actively pruning pipelines and shifting portfolios—Pfizer cut 14 programs while AstraZeneca added 20—suggesting strategic reallocation rather than industry-wide expansion
• •Oncology dominance persists at 38.6% of new entries while neurology gains momentum (14.4% in 2025 vs. 12.7% in 2023), indicating market-driven concentration in high-value therapeutic areas; monitor whether pipeline stagnation signals innovation ceiling or temporary consolidation phase

RochePfizerAstraZeneca

→ Read original article

Market Access•Fierce Biotech•Apr 2, 2026

Cancer screening costs rival diagnosis fears as patients fall behind

background ▾

• •73% of U.S. adults are behind on routine cancer screenings; cost concerns cited by 34% of worried patients, up 9 percentage points year-over-year
• •Patient confusion about financial responsibility for covered screenings is a significant barrier—many don't realize Medicare/Medicaid cover routine screening despite variable coverage by cancer type and risk level
• •This trend suggests opportunity for payers, healthcare systems, and screening manufacturers to improve patient communication and financial transparency to reverse the screening backlog

Prevent Cancer Foundation

→ Read original article

Clinical Trials

No articles for this category on this date.